甘草酸在慢性丙型肝炎患者中的长期疗效。

The long term efficacy of glycyrrhizin in chronic hepatitis C patients.

作者信息

Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H

机构信息

Department of Gastroenterology, Tonanomon Hospital, Minato-ku, Tokyo, Japan.

出版信息

Cancer. 1997 Apr 15;79(8):1494-500. doi: 10.1002/(sici)1097-0142(19970415)79:8<1494::aid-cncr8>3.0.co;2-b.

DOI:10.1002/(sici)1097-0142(19970415)79:8<1494::aid-cncr8>3.0.co;2-b

PMID:9118029

Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) occurs in patients with hepatitis C virus-RNA positive chronic liver disease. It is important to prevent HCC with drug administration.

METHODS

A retrospective study was undertaken to evaluate the long term preventive effect of Stronger Neo-Minophagen C (SNMC) on HCC development. SNMC is a Japanese medicine that is commonly administered to patients with chronic hepatitis C to improve the serum alanine aminotransferase (ALT) level. Of 453 patients diagnosed with chronic hepatitis C retrospectively in the study hospital between January 1979 and April 1984, 84 patients (Group A) had been treated with SNMC; SNMC was given at a dose of 100 mL daily for 8 weeks, then 2-7 times a week for 2-16 years (median, 10.1 years). Another group of 109 patients (Group B) could not be treated with SNMC or interferon for a long period of time (median, 9.2 years) and were given other herbal medicine (such as vitamin K). The patients were retrospectively monitored, and the cumulative incidence of HCC and risk factors for HCC were examined.

RESULTS

The 10th-year rates of cumulative HCC incidence for Groups A and B were 7% and 12%, respectively, and the 15th-year rates were 12% and 25%. By Cox regression analysis, the relative risk of HCC incidence in patients not treated with SNMC (Group B) was 2.49 compared with that of patients treated with SNMC (Group A).

CONCLUSIONS

In this study, long term administration of SNMC in the treatment of chronic hepatitis C was effective in preventing liver carcinogenesis.

摘要

背景

丙型肝炎病毒RNA阳性的慢性肝病患者会发生肝细胞癌（HCC）。通过药物治疗预防HCC很重要。

方法

进行了一项回顾性研究，以评估强力新（SNMC）对HCC发生的长期预防效果。SNMC是一种日本药物，常用于慢性丙型肝炎患者以改善血清丙氨酸氨基转移酶（ALT）水平。1979年1月至1984年4月在研究医院回顾性诊断为慢性丙型肝炎的453例患者中，84例患者（A组）接受了SNMC治疗；SNMC的给药剂量为每日100 mL，持续8周，然后每周2 - 7次，持续2 - 16年（中位数为10.1年）。另一组109例患者（B组）长期无法接受SNMC或干扰素治疗（中位数为9.2年），接受了其他草药治疗（如维生素K）。对患者进行回顾性监测，并检查HCC的累积发病率和HCC的危险因素。